arrow
C

Christine Lacabaratz

vaccine research institute
H指数:32
被引数:4,444

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and immunogenicity of CD40.HIVRI.Env, a dendritic cell-based HIV vaccine, in healthy HIV-uninfected adults: a first-in-human randomized, placebo-controlled, dose-escalation study (ANRS VRI06)
2024-11-010
OAAI
Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection
2022-07-089
OA
T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial
2022-06-158
OA
Design, immunogenicity, and efficacy of a pan- sarbecovirus dendritic-cell targeting vaccine
2022-06-0117
OAAI
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial
2022-01-1140
OAAI
Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques
2021-09-0125
OAAI
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial
2021-04-01119
OAAI
Long-lasting severe immune dysfunction in Ebola virus disease survivors
2020-07-2443
OAAI
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial
2020-06-2610
OAAI